Skip to content

medcelerator · clinician one-pager

New Daily Pill for Chronic Weight Management in Adults

Foundayo (orforglipron) for chronic weight management

FDA Approved · United States, Canada, United Kingdom · September 4, 2026

Condition: Obesity

Who this is for

FDA labelled oral orforglipron for chronic weight management in adults. UK MHRA also labelled weight management and type 2 diabetes — those lines stay separate. Health Canada under review. Authorized is not funded.

Next clinical step

The US Food and Drug Administration (FDA) has approved this medicine. In the United States and the United Kingdom, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed. In Canada, authorisation is not confirmed; see Possible routes below if any are listed.

Ways to access this treatment

Search all trials on ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=obesity&intr=orforglipron&aggFilters=status:rec

Search Health Canada's Clinical Trials Search Portal: https://clinical-trials-search.canada.ca/en/search?search_api_fulltext=orforglipron

Possible routes (not confirmed)

General resources for further research

AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/foundayo-orforglipron